Sign In
Buy DYN
$25.18
-0.550 (-2.14%)
At Close: Jul 31, 2026
LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therape
NEW YORK CITY, NY / ACCESSWIRE / September 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company")
An Investigation Has Been Launched Into Dyne Therapeutics Inc For Fraudulent Practices And Shareholders Can Assist The Schall Law Firm
11:00am, Saturday, 14'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therape
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
04:30pm, Friday, 13'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ:DYN). Such investors are advi
LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therape
NEW YORK CITY, NY / ACCESSWIRE / September 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company")
Dyne Therapeutics Inc May Have Committed Securities Fraud And The Schall Law Firm Invites Stakeholders To Join An Inquiry
11:00am, Thursday, 12'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therape
NEW YORK CITY, NY / ACCESSWIRE / September 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company")
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. (“Dyne” o
Dyne Therapeutics, Inc. (DYN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
03:55pm, Wednesday, 11'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerni
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
03:30pm, Wednesday, 11'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ:DYN). Such investors are advi
Dyne Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - DYN
11:30am, Wednesday, 11'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerni
LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therape
NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerni
Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc.(DYN) And Encourages Investors to Connect
10:00am, Wednesday, 11'th Sep 2024
NEW YORK CITY, NY / ACCESSWIRE / September 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company")
